The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Abstract
Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. Methods: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. Results: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers is of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of ∼2–9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria. Conclusions: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Duffy, M. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.624 · Cited by 794
Self-citationIntensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial
Del Turco, M. R. (1994) · JAMA · doi:10.1001/jama.1994.03510440053032 · Cited by 497
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2843 · Cited by 353
Follow-up strategies for women treated for early breast cancer
Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001768.pub3 · Cited by 338
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Self-citationHuman MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
Ren, J., Agata, N., Chen, D., Li, Y., Yu, W.-H., Huang, L., Raina, D., Chen, W., Kharbanda, S., & Kufe, D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00020-0 · Cited by 325
Cited by
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Biosensors: the new wave in cancer diagnosis
Mousa, S. (2010) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s13465 · Cited by 381
Di Leva, G., & Croce, C. M. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.01.004 · Cited by 356
Metadata
- Authors
- Duffy, M. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03-01
- Volume
- 52
- Issue
- 3
- Pages
- 345-351
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2170481258
- Cited by
- 460
- References
- 35
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? https://app.cochat.ai/papers/10.1373/clinchem.2005.059832
- The paper
- Duffy, M. J. (2006). Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? Clinical Chemistry. https://doi.org/10.1373/clinchem.2005.059832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.